diABZI STING agonist-1 (Tautomerism) (diABZI STING agonist (Compound 3)) is a selective stimulator of interferon genes (STING) receptor agonist, with EC50s of 130, 186 nM for human and mouse, respectively.

diABZI STING agonist-1 (Tautomerism) is a selective stimulator of interferon gene (STING) receptor agonists, with EC50 of 130 and 186 nM for humans and mice, respectively. diABZI STING agonist-1 (Tautomerism) at a concentration of 1 μM showed high selectivity for more than 350 kinases tested[1].

diABZI STING agonist-1 (Tautomerism)(subcutaneous injection; 2.5 mg/kg) induces STING-dependent activation of type I interferon and proinflammatory cytokines in vivo. diABZI STING agonist-1 (Tautomerism) (intravenous; 3 mg/kg) exhibited systemic exposure with a half-life of 1.4 hours and reached a systemic concentration greater than half the maximum effective concentration of STING in mice (EC50) 200 ng/kg) ml). diABZI STING agonist-1 (Tautomerism) (intravenous; 1.5 mg / kg; 43 days) can significantly inhibit tumor growth and significantly improve survival rate (P <0.001). Eight out of 10 mice are tumor-free[1].